Latest Breaking News On - Vera therapeutics - Page 1 : comparemela.com

JPMorgan Chase & Co Increases Vera Therapeutics (NASDAQ:VERA) Price Target to $65 00

JPMorgan Chase & Co Increases Vera Therapeutics (NASDAQ:VERA) Price Target to $65 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Raymond jamesJosephr youngChina universal asset management coVera therapeutics incCetera advisorsSecurities exchange commissionSg americas securitiesJpmorgan chase coAmeritas investment partners incVera therapeuticsGet free reportExchange commissionUniversal asset managementInvestment partnersVera therapeutics daily

Vera Therapeutics Says FDA Grants Breakthrough Therapy Designation For Atacicept To Treat IgAN

Biotechnology company Vera Therapeutics, Inc. (VERA) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of Immunoglobulin A Nephropathy or IgAN.

Drug administrationVera therapeutics incVera therapeuticsBreakthrough therapy designation

Vera Therapeutics, Inc Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics, Inc Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Richard lafayetteVera therapeutics incCongress paper selection committeeEuropean renal association congressVera therapeuticsPaper selectionFree communicationOpen label extensionIga nephropathyPersistent proteinuriaStanford glomerular disease centerStanford university medical

Vera Therapeutics, Inc (NASDAQ:VERA) Given Consensus Recommendation of Buy by Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The […]

United statesRaymond jamesJosephr youngVera therapeutics company profileVera therapeutics incVirtu financialFirst light asset managementArtal groupVera therapeuticsGet free reportState teachers retirement systemCapital managementTherapeutics stock downGet freeVera therapeutics daily

New York State Common Retirement Fund Increases Stock Position in Vera Therapeutics, Inc (NASDAQ:VERA)

New York State Common Retirement Fund increased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 55.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,491 shares of the company’s stock after buying an additional 6,244 shares during the period. New York State Common Retirement Fund’s holdings in Vera […]

New yorkUnited statesRaymond jamesMaha katabiJosephr youngZurcher kantonalbank zurich cantonalbankBarclays plcSwiss national bankVera therapeutics incYork state common retirement fundVera therapeutics company profileMirae asset global investments coSecurities exchange commissionNew york state common retirement fundVera therapeuticsFree report